Saturday 7 November 2026 Export ATXI’s income statement to Excel — free account

Avenue Therapeutics, Inc.

ATXI Healthcare Biotechnology

Avenue Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million.

EPS: −290.9%
Free cash flow: −169.9%

Quarter to June 2026, against a year earlier

0.43 0.03 +7.50%

Follow ATXI

Alert me

Market cap: $680.0K
P/E: 0.0×
Fwd P/E: −0.4×
Dividend yield: —
F-score: n/a
Altman Z: −51.47
Beneish M: n/a
Dividend safety: n/a

Overview

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
ROE Full definition →	+8 more TTM periods Free account	(189.33%)	(157.75%)	(99.26%)	(163.30%)
ROA Full definition →		(117.92%)	(103.84%)	(57.80%)	(90.50%)
ROIC Full definition →		0.00%	0.00%	0.00%	0.00%
Return on Tangible Assets Full definition →		(162.57%)	(158.79%)	(146.24%)	(488.05%)
Average Days of Receivables Full definition →		—	—	—	—
Free Cash Flow per Share Full definition →		(0.55)	(0.59)	(0.33)	(0.42)
Free Cash Flow Full definition →		(1.74)	(1.83)	(1.08)	(1.38)
Other line items
Cash ROIC Full definition →		(28.99%)	(39.11%)	(30.01%)	(55.12%)
Accounts Payable Turnover Full definition →		0.00	0.00	0.00	0.00
Average Days of Payables Full definition →		0.00	0.00	0.00	0.00
Tax Rate Full definition →		0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Share Based Compensation of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Operating CF/Net income Full definition →		0.47	0.63	0.62	0.50
Revenue per Share Full definition →		0.00	0.00	0.00	0.00
Operating CF per Share Full definition →		(0.55)	(0.59)	(0.33)	(0.42)
Capex per Share Full definition →		0.00	0.00	0.00	0.00

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026